Irinotecan Hydrochloride

Xi'an Huawave Biotech Co., Ltd. is a professional Irinotecan Hydrochloride manufacturer and Irinotecan Hydrochloride supplier . We are committed to providing customers with professional research and development, production and sales, as well as OEM and ODM processing services.
Irinotecan Hydrochloride is a drug with multiple efficacy, primarily used for the treatment of metastatic colorectal cancer in adults, and it serves as a second-line treatment option for patients who have failed prior chemotherapy containing 5-FU. Below are the main efficacy of Irinotecan Hydrochloride:

Antitumor Activity:
Irinotecan Hydrochloride can interfere with DNA synthesis and the assembly process of microtubule proteins, thereby inhibiting cancer cell proliferation.
It is a highly selective topoisomerase I inhibitor that specifically binds to DNA, causing single-strand DNA damage and inducing tumor cell death.
By disrupting the strand-passing function of topoisomerase I, it obstructs DNA replication, achieving an antitumor effect.

Immunomodulatory Effect:
Irinotecan Hydrochloride can influence the body's immune response, including enhancing or suppressing the activity of specific cells and molecules, thereby regulating the immune system.

Antiemetic Effect:
Irinotecan Hydrochloride can reduce the excitability of the nausea and vomiting center. Its mechanism may involve blocking opioid receptors or inhibiting 5-hydroxytryptamine receptors in the central nervous system, thereby exerting an antiemetic effect.

Anti-inflammatory Effect:
Irinotecan Hydrochloride can block the cyclooxygenase pathway during arachidonic acid metabolism, thereby reducing the synthesis of the inflammatory mediator prostaglandin, producing a certain anti-inflammatory effect.
It can also achieve an anti-inflammatory effect by inhibiting the release of inflammatory mediators and reducing the migration of white blood cells.

Antidiarrheal Effect:
Irinotecan Hydrochloride can reduce intestinal motility, thereby alleviating diarrhea symptoms.

However, when using Irinotecan Hydrochloride, the following points need to be noted:

Monitor hematological parameters, as the drug may cause hematological toxicity such as decreased white blood cell count.
Avoid concurrent use with other drugs that may cause bone marrow suppression to reduce the occurrence of adverse reactions.
Patients should observe changes in their bodies during treatment with this drug and promptly inform their doctor if any abnormalities occur.

In addition, Irinotecan Hydrochloride is also used clinically for the treatment of other tumor diseases, such as colon cancer, rectal cancer, ovarian cancer, breast cancer, non-small cell lung cancer, pancreatic cancer, gastric cancer, etc., but specific use should follow medical advice. When using Irinotecan Hydrochloride for treatment, patients may experience adverse reactions such as nausea, vomiting, diarrhea, stomatitis, rash, etc. If the symptoms are mild, no special treatment is generally required; if the symptoms are severe, medical attention should be sought promptly.

Overall, Irinotecan Hydrochloride is an antitumor drug with multiple efficacy, but attention should be paid to its possible adverse reactions and precautions when using it. Consult a professional doctor before use to ensure the safety and effectiveness of the medication.

Irinotecan Hydrochloride is a broad-spectrum anticancer drug with various applications. Below is a detailed introduction to its applications:

I. Main Uses

Colorectal Cancer:

• It is most commonly used in the treatment of colorectal cancer, particularly in combination with 5-fluorouracil and leucovorin for patients with advanced colorectal cancer who have not previously received chemotherapy.
• It is used as adjuvant therapy for postoperative patients.
• It is used as a single agent for patients who have failed treatment with 5-fluorouracil-containing chemotherapy regimens.

Other Tumors:

• Irinotecan Hydrochloride is also commonly used as second-line treatment for pancreatic cancer and gastric cancer.
• It is also used in third-line or higher chemotherapy for lung cancer.
• In addition, it is used to treat various tumor diseases such as ovarian cancer, breast cancer, and non-small cell lung cancer.

II. Mechanism of Action

The main mechanism of action of Irinotecan Hydrochloride is to interfere with the synthesis of cancer cell DNA and disrupt the assembly process of microtubule proteins, thereby inhibiting cancer cell proliferation. As a highly selective topoisomerase I inhibitor, it can specifically bind to DNA, causing single-strand DNA damage and inducing tumor cell death.

III. Dosage and Administration

Recommended Dose: The recommended dose of Irinotecan Hydrochloride is usually 350mg/m², administered through intravenous infusion over 30 to 90 minutes, once every three weeks.
Dose Adjustment: For patients with asymptomatic severe neutropenia, neutropenia accompanied by fever or infection, severe diarrhea, and other symptoms, the dose should be adjusted based on specific circumstances.
Delayed Administration: Administration should be postponed until the patient's neutrophil count recovers to a certain level or if severe adverse reactions have occurred previously.

IV. Precautions

Allergic Reactions: Before administration, it should be ensured that the patient does not have an allergic reaction to Irinotecan Hydrochloride and its active metabolites.
Monitoring Indicators: During treatment with Irinotecan Hydrochloride, patients' blood routine, liver function, and kidney function should be closely monitored.
Cardiac Evaluation: For patients with cardiovascular diseases, a cardiac evaluation should be conducted before using Irinotecan Hydrochloride.
Drug Interactions: Avoid concomitant use with other drugs that may cause bone marrow suppression to reduce the occurrence of adverse reactions.
Special Populations: Irinotecan Hydrochloride should be used with caution in pregnant and lactating women. The safety and effectiveness of Irinotecan Hydrochloride in children have not been established, so it should not be used.

V. Adverse Reactions

During treatment with Irinotecan Hydrochloride, patients may experience adverse reactions such as nausea, vomiting, diarrhea, stomatitis, and rash. If the symptoms are mild, no specific treatment is generally required; if the symptoms are severe, medical attention should be sought promptly.

In summary, Irinotecan Hydrochloride plays an important role in the treatment of various tumors as a broad-spectrum anticancer drug. However, attention should be paid to possible adverse reactions and precautions during use to ensure the safety and effectiveness of the medication.